Syk Inhibitor

MK-8457 is a dual inhibitor of spleen tyrosine kinase (SYK) and zeta-chain-associated protein kinase 70 (ZAP70). MK-8457 can be used for the researches of rheumatoid arthritis, hypertension.

Syk-IN-16 is a spleen tyrosine kinase (SYK) inhibitor with an IC₅₀ of 16.0 nM. Syk-IN-16 exerts antiproliferative effects, induces cell apoptosis, inhibits cell migration and increases DNA damage in cancer cells. Syk-IN-16 suppresses tumor growth in xenograft models without obvious toxicity. Syk-IN-16 can be used for the research of triple-negative breast cancer.

BI 894416 is a spleen tyrosine kinase (SYK) inhibitor. BI 894416 has a deuterium-labeled derivative that can be used as an internal standard for bioanalytical studies. BI 894416 is applicable to the research of severe asthma.

Syk Inhibitor II dihydrochloride dihydrate is a potent, high selective and ATP-competitive Syk inhibitor with an IC₅₀ of 41 nM. Syk Inhibitor II dihydrochloride dihydrate inhibits 5-HT release from RBL-cells with an IC₅₀ of 460 nM. Syk Inhibitor II dihydrochloride dihydrate shows less potent against other kinases and has anti-allergic effect.

SYK/JAK-IN-1 is a dual Syk/Jak2 kinase inhibitor. SYK/JAK-IN-1 is applicable to cancer-related research.

(rel)-PRT062607 ((rel)-P505-15) is the relative configuration of PRT062607 (HY-15322). PRT062607 is a highly selective inhibitor of Syk kinase, with an IC₅₀ value of 1-2 nM, and is more than 80 times less potent against Fgr, Lyn, FAK, Pyk2, and Zap70.

Syk-IN-7 (compound 17) is an inhibitor of spleen tyrosine kinase (SYK).

Syk-IN-2 (Page 78; 35) is a spleen tyrosine kinase (Syk) inhibitor.

NMS-0963 (compound 1) is an inhibitor of spleen tyrosine kinase (SYK) with an oral activity and IC₅₀ value of 3 nM. NMS-0963 inhibits BaF3-TEL/SYK cell line proliferative at 27 nM.

IQS-019 is a B cell receptor (BCR) kinase inhibitor. IQS-019 can inhibit the de-phosphorylation of constitutive and IgM-activated Syk, Lyn, and Btk. IQS-019 can inhibit cell proliferation, migration and induce apoptosis. IQS-019 exhibits antitumor activity and can be used for the research of cancer, such as B cell lymphoma.

Entospletinib (Standard) is the analytical standard of Entospletinib. This product is intended for research and analytical applications. Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with an IC50 of 7.7 nM.

Alisol B 23-acetate (Standard) is the analytical standard of Alisol B 23-acetate (HY-N0805). This product is intended for research and analytical applications. Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma.

TOP1288 is a narrow spectrum kinase inhibitor for P38α, Src and Syk kinase, with IC₅₀ of 116nM, 24nM and 659nM, respectively. TOP1288 inhibits inflammatory cytokine release from inflamed biopsies and myofibroblasts.

Type-II-IN-1 (Compound 3) is a type II spleen tyrosine kinase (Syk) inhibitor with an IC₅₀ of 2.1 nM. Type-II-IN-1 can bind to the DFG-out conformation of Syk. Type-II-IN-1 can be used for the research of immunology, such as asthma.

Dehydroabietinol is a SYK inhibitor with an IC₅₀ of 46.4 μM. Dehydroabietinol inhibits the growth of Trypanosoma cruzi epimastigotes, Leishmania braziliensis promastigotes and Leishmania infantum promastigotes. Dehydroabietinol indirectly inhibits the growth of Plasmodium falciparum, alters the erythrocyte membrane, and induces spherostomatocyte transformation and endovesicle formation. Dehydroabietinol can be used in studies related to immune-mediated diseases, Chagas disease, leishmaniasis and malaria.

Gusacitinib (Standard) is the analytical standard of Gusacitinib (HY-103018). This product is intended for research and analytical applications. Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma.

Syk-IN-13 (Compound A90) is a Syk inhibitor, and can be used for research of rheumatoid arthritis and/or systemic lupus.

Entospletinib dimesylate (GS-9973 dimesylate) is an orally bioavailable, selective Syk inhibitor with an IC₅₀ of 7.7 nM.

Lanraplenib succinate (Standard) is the analytical standard of Lanraplenib (succinate) (HY-109091B). This product is intended for research and analytical applications. Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC₅₀=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.

SYK-IN-14 is an orally active Syk and ZAP-70 inhibitor with human Syk IC₅₀ of 0.006 μM, human ZAP-70 IC₅₀ of 0.23 μM. SYK-IN-14 functionally inhibits Syk kinase activity in vitro. SYK-IN-14 functionally inhibits ZAP-70 kinase activity in vitro. SYK-IN-14 suppresses passive cutaneous anaphylaxis reaction in Mus musculus mice. SYK-IN-14 suppresses Concanavalin A (HY-P2149)-induced IL-2 production in Mus musculus mice. SYK-IN-14 can be used for the research of allergic disorders and autoimmune diseases.